Medullary Thyroid Carcinoma (MTC)
A rare thyroid cancer arising from C-cells — personal or family history rules out GLP-1 medications.
Medullary thyroid carcinoma is a rare cancer of the thyroid's calcitonin-producing C-cells, accounting for a small percentage of thyroid cancers and sometimes running in families through RET gene mutations. It matters here because rodent studies of GLP-1 agonists showed C-cell tumors, producing the class boxed warning.
The resulting rule is absolute and simple: any personal or family history of MTC — or of MEN 2, the syndrome that includes it — means no semaglutide, no tirzepatide, no exceptions, which is why every honest intake asks the question. For everyone else, no increase in human MTC has been established, but symptoms like a persistent neck lump or hoarseness during treatment warrant prompt evaluation.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Medullary Thyroid Carcinoma? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment